Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838347 | 0.94 | CACNA1I (0.46) | CACNA1IKCNH2CHRNA7TAS1R3TAS1R2 | |
| SCHEMBL18838333 | 0.89 | CACNA1I (0.45) | CACNA1IKCNH2CHRNA7TAS1R3TAS1R2 | |
| SCHEMBL18860345 | 0.87 | CACNA1I (0.59) | CACNA1IKCNH2CACNA1HCACNA1G | |
| SCHEMBL18860280 | 0.87 | KCNH2 (0.60) | CACNA1IKCNH2CHRNA7TAS1R3TAS1R2 | |
| SCHEMBL18860274 | 0.85 | KMT2A (0.43) | CACNA1ICACNA1HCACNA1GALDH1A1LMNA | |
| SCHEMBL18860276 | 0.82 | CHRNA7 (0.46) | CACNA1IKCNH2CHRNA7TAS1R3TAS1R2 | |
| SCHEMBL18860180 | 0.81 | CACNA1I (0.61) | CACNA1IKCNH2CACNA1HCACNA1G | |
| SCHEMBL18860178 | 0.81 | CACNA1I (0.61) | CACNA1IKCNH2CACNA1HCACNA1G | |
| SCHEMBL18838359 | 0.81 | CACNA1I (0.61) | CACNA1IKCNH2CACNA1HCACNA1G | |
| SCHEMBL18860332 | 0.81 | KMT2A (0.54) | KCNH2CHRNA7UTS2RKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | CACNA1I 1/4885KCNH2 55/4885CHRNA7 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.